Boston Scientific Corporation (BSX)
NYSE · Healthcare · Medical Devices
$42.40−0.47%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $61.5B
- P/E (trailing)
- 17.2
- Forward P/E
- 12.5
- 52-week range
- $41.94 – $105.65
- 52-week change
- −55.95%
- EPS (trailing)
- $2.47
- Analyst rating
- 1.6 Buy
- Next earnings
- Oct 28, 2026
Fiscal year to Dec 2025
- Revenue
- $20.1B (+19.87%)
- Operating margin
- 18.0%
- Diluted EPS
- $1.94
- Free cash flow
- $3.7B
From the company’s annual report on SEC EDGAR.
About Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems.
Headquarters: Marlborough, United States · 59,000 employees · bostonscientific.com